Xin Lang Cai Jing·2025-05-23 01:39Group 1 - The core viewpoint of the news highlights the approval of a new innovative drug by Heng Rui Medicine, which is the first self-developed DPP-4 inhibitor combined with metformin in China, aimed at improving blood sugar control for adult patients with type 2 diabetes [1] - Following the announcement, Heng Rui Medicine's stock surged nearly 30% in the Hong Kong market, indicating strong investor confidence in the innovative drug sector [1] - The Hong Kong innovative drug index has seen a significant decrease in its price-to-earnings ratio from 64 times on February 21 to 25 times on May 22, suggesting a favorable investment opportunity in the sector [1] Group 2 - The Hong Kong innovative drug ETF (159567) tracks the National Index for Hong Kong Innovative Drugs, with 90% of its weight in innovative drug companies, positioning it to benefit from trends such as AI-enabled drug development and the expansion of domestic innovative drugs [2] - The larger innovative drug ETF (159992) encompasses leading companies in the innovative drug industry chain, benefiting from advancements in AI, the internationalization of domestic innovative drugs, and the introduction of new healthcare policies [2] - According to Xingye Securities, the innovative drug sector in China is transitioning from a "follower" to a "leader," with significant advancements expected in new targets and technologies by 2025, showcasing strong global competitiveness in areas like ADC, bispecific antibodies, and cell therapy [2]